Glipizide Extended-Release Tablets — Class III drug recall D-1058-2017
Terminated recall by Teva Pharmaceuticals USA, reported 2017-08-16, distributed in CT, IL, MI, OH, PA, VA. Failed Moisture Limits: out of specification test results for water content obtained during stability testing.
| Recall number | D-1058-2017 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA, North Wales, PA, United States |
| Recall initiated | 2017-08-02 |
| Classified | 2017-08-08 |
| Reported by FDA | 2017-08-16 |
| Terminated | 2018-02-28 |
| Distributed | CT, IL, MI, OH, PA, VA |
| Reason classes | specification failure |
| NDC | 00591-0844-15 |
| Lot numbers | 3138405A |
| Expiration dates | 2017-08 |
Product
Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose blister pack per carton, Rx only, Mfd for: Watson Laboratories, Inc., Corona, CA 92880, Mfd by: Patheon Pharmaceuticals, Inc., Cincinnati, OH 43215, NDC 0591-0844-15
Reason for recall
Failed Moisture Limits: out of specification test results for water content obtained during stability testing.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1058-2017. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.